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Abstract
Aims: Storkhead box 1 (STOX1) is a winged-helix transcription factor that is implicated in the genetic forms of
a high-prevalence human gestational disease, pre-eclampsia. STOX1 overexpression confers pre-eclampsia-like
transcriptomic features to trophoblastic cell lines and pre-eclampsia symptoms to pregnant mice. The aim of
this work was to evaluate the impact of STOX1 on free radical equilibrium and mitochondrial function, both
in vitro and in vivo. Results: Transcriptome analysis of STOX1-transgenic versus nontransgenic placentas at
16.5 days of gestation revealed alterations of mitochondria-related pathways. Placentas overexpressing STOX1
displayed altered mitochondrial mass and were severely biased toward protein nitration, indicating nitroso-
redox imbalance in vivo. Trophoblast cells overexpressing STOX1 displayed an increased mitochondrial
activity at 20% O2 and in hypoxia, despite reduction of the mitochondrial mass in the former. STOX1 over-
expression is, therefore, associated with hyperactive mitochondria, resulting in increased free radical produc-
tion. Moreover, nitric oxide (NO) production pathways were activated, resulting in peroxynitrite formation. At
low oxygen pressure, STOX1 overexpression switched the free radical balance from reactive oxygen species
(ROS) to reactive nitrogen species (RNS) in the placenta as well as in a trophoblast cell line. Innovation: In
pre-eclamptic placentas, NO interacts with ROS and generates peroxynitrite and nitrated proteins as end
products. This process will deprive the maternal organism of NO, a crucial vasodilator molecule. Conclusion:
Our data posit STOX1 as a genetic switch in the ROS/RNS balance and suggest an explanation for elevated
blood pressure in pre-eclampsia. Antioxid. Redox Signal. 21, 819–834.
Introduction
Pre-eclampsia, a widespread disease of pregnancy, af-fects 2%–8% of women (66) and is responsible for
50,000 maternal deaths worldwide (9). This syndrome,
characterized by de novo hypertension and proteinuria, is
considered to originate from placental defects (35). Usually,
uterine arteries are invaded by extra-villous cytotrophoblasts
that reach the first third of the myometrium, replace maternal
endothelial cells and, ultimately, adopt an endothelial phe-
notype. Consistently, oxygen pressure progresses from 1.5–
2% during early gestation to around 10% at late time points
(33). In pre-eclamptic pregnancies, maternal uterine arteries
are not deeply colonized, resulting in insufficient or irregular
blood flow to the fetus (25). A landmark of hypoxia, the
hypoxia-inducible miRNA miR-210 (15), is up-regulated
in pre-eclampsia (32). Transitory local hypoxic/hyperoxic
changes exceedingly erode the syncytiotrophoblast and
shed debris into maternal circulation. These debris release
vasoactive substances such as endothelin 1 (55) and anti-
angiogenic factors (notably sFLT-1 and sENG), thus con-
tributing to the maternal systemic endothelial injury.
Reactive oxygen species (ROS) and reactive nitrogen
species (RNS) have been associated with pre-eclampsia (46,
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57, 74). Mitochondrial mass (mitochondria being major
sources of ROS/RNS) is increased in pre-eclamptic placentas
(72). However, when cytotrophoblast cells are isolated from
these defective placentas, the expression of mtDNA and
nuclear respiratory factor 1 (NRF1) (linked to the mito-
chondrial mass) is abnormally low (43). Proteomics analysis
of severe pre-eclamptic placentas revealed altered mito-
chondria-related pathways such as fatty acid oxidation (4),
ROS generation, and oxidative stress (64).
Overexpression of the storkhead box 1 (STOX1) tran-
scription factor (71) induces transcriptome alteration, mim-
icking pre-eclampsia in choriocarcinoma JEG-3 cells, used
as proxies for trophoblast cells (56), and induces a pre-
eclampsia-like syndrome in vivo in a transgenic mouse model
(18). Major transcriptome alterations in cells overexpressing
STOX1 involve several cellular pathways, among which the
mitochondrial function is highly represented (56). This
prompted us to further investigate how STOX1 regulates the
mitochondrial function and ROS/RNS balance. In the present
study, STOX1 overexpression in transgenic placentas and
trophoblast cells strongly altered the ROS/RNS metabolism
and mitochondrial function. The novel transcription factor
STOX1 appears as a major regulator of the nitroso-redox
balance and mitochondrial homeostasis, possibly depriving
the maternal vascular system of nitric oxide (NO), a major
agent of endothelium health. In cells overexpressing STOX1,
the major hypoxamir miR-210 (29) is virtually extinguished,
suggesting that trophoblast cells become unable to adapt to
low O2 concentration.
Results
STOX1 placentas display massive deregulation
of genes involved in mitochondrial function
The transcriptomes of 16.5 days post fertilization (dpc)
transgenic versus wild-type (WT) placentas were compared,
using Gene Set Enrichment Analysis (GSEA, see Materials
and Methods section). Among 962 gene groups or pathways
analyzed, 373 were identified as significant (false discovery
rate [FDR] < 0.25). Strikingly, 12 out of 13 mitochondria-
related pathways belonged to this group ( p= 6.6· 10- 5, with
FDR ranging from 0.017 to 0.21). The list of pathways and
gene groups is provided in Supplementary Table S1 (Sup-
plementary Data are available online at www.liebertpub.com/
ars). As an example, genes relevant to the cluster ‘‘Mi-
tochondrial Part’’ are listed in Supplementary Figure S1, and
Supplementary Table S2. In sum, major alterations of gene
expression in STOX1 transgenic placentas at 16.5 days of
gestation clearly targeted mitochondria, confirming the data
obtained in the cellular model.
STOX1 overexpression in transgenic placentas induces
altered mitochondrial mass and nitroso-redox imbalance
The mitochondrial mass, evaluated by the steady-state
immunofluorescence of the outer membrane mitochondrial
marker TOM22 (39), was significantly higher (approximately
fourfold) in pre-eclamptic than in control placentas, at least in
the Labyrinth and the Junctional zone (Fig. 1A, B), similar to
what is observed in human pre-eclamptic placentas (43).
TOM22 (and porine voltage-dependent anion channel [VDAC])
global increase in pre-eclamptic placentas was confirmed by
Western blots (Fig. 1C). This result prompted us to analyze free
radical production in placentas. For this, we evaluated the
steady-state levels of protein oxidative adducts, either (ROS-
dependent) carbonylation or (RNS-dependent) nitration (65,
69), using dinitrophenyl or 3-nitrotyrosine immunostaining,
respectively. We observed a striking signal inversion between
transgenic and nontransgenic placentas (Fig. 1D, E). Transgenic
placentas displayed dramatically higher levels of nitrated pro-
teins and lower levels of carbonylated proteins than controls, in
each placental compartment. These in vivo results point to
STOX1 as a crucial regulator of the nitroso-redox balance in the
placenta.
STOX1 overexpression deregulates genes involved
in the response to hypoxia, redox balance, nitric oxide,
and energy metabolism
We then analyzed gene expression in JEG-3 trophoblasts
[control and STOX1High, obtained in a previous study (56)]
by RT-qPCR; primers are described in Supplementary Table
S3. Since oxygen is a signaling molecule in trophoblasts (11),
we cultivated both cell types at either 2% or 20% O2. Two
percent O2 is compatible with oxygen concentrations of early
gestation. Twenty percent O2, higher than natural oxygen
concentrations, was, nevertheless, chosen to compare our
results with most available studies based on trophoblasts
cultivated at atmospheric pressure. STOX1High cells ex-
pressed STOX1 at a high level in both conditions (Fig. 2A).
STOX1High cells in hypoxia recapitulated metabolic
alterations observed in pre-eclampsia, as decreased DNA
damage response (DDR) (Supplementary Fig. S2A), and de-
creased expression of genes involved in cholesterolmetabolism,
SREBP1A, and SREBP1C (28) (Supplementary Fig. S2B).
At 2% O2, expression of the two crucial modulators of the
hypoxia responseHIF1a andHIF1bwas moderately affected
by hypoxia (Fig. 2A). The hypoxamir miR-210 levels were
not altered in STOX1 overexpressing cells at 20% O2.
Strikingly, however, at 2% O2miR-210 expression increased
by*6-fold in control cells and decreased by*30-fold in
STOX1High cells compared with 20% O2, resulting in a
dramatically reduced level (*180-fold) of miR-210 in
STOX1High cells under hypoxia.
Innovation
In this study, we show that a unique transcription factor,
storkhead box 1 (STOX1), induces opposite O2-dependent
effects on reactive oxygen species (ROS) and reactive
nitrogen species (RNS) production in vitro as well as
in vivo in a murine model of pre-eclampsia. We show a
striking predominance of RNS in STOX1 transgenic pla-
centas, suggesting that NO is rapidly associated with ROS
and generates ONOO - . This would deprive endothelial
cells from the essential vasodilating action of NO, thereby
giving a rationale to the systemic hypertension of mice
with transgenic (pre-eclamptic) placentas. Nitroso-redox
imbalance could be considered the causative element in
pre-eclampsia-induced hypertension and other vascular
diseases. These observations may have implications for
human pathogenesis and therapeutics.
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FIG. 1. In vivo alterations of mitochondria and nitroso-redox balance in transgenic STOX1 overexpressing placentas. (A)
Structure of the murine placenta. (B) Three-dimensional-reconstructed placenta regions (Labyrinth, Glycogen cells, Junctional zone,
and Maternal cells) stained with TOM22 (green) and counterstained with Hoechst in mice from WT·WT and WT·TgSTOX42
crosses. Right panels indicate fluorescence intensity quantification per surface (area) analyzed; identical surfaces were assessed in all
samples; n=500 surfaces (Labyrinth), and n=100 surfaces (Glycogen cells, Junctional zone, and Maternal cells) per tissue section.
Scale bar=50lm. (C) Western blot of mitochondrial markers TOM22 and VDAC, of internal reference GAPDH, and of stained
membrane with loading control SYPRO Ruby on protein extracts from five WT·WT and five WT·HT42 placentas, with quan-
tification by densitometry. Despite the blurring due to the presence of several cell types in the placentas, the differencewas significant
at p<0.05 with VDAC (asterisk). (D, E) Three-dimensional-reconstructed placenta regions (Labyrinth, Glycogen cells, Junction
zone, andMaternal cells) stained with (D) 3-nitrotyrosine antibody to detect protein nitration, or (E) treated with DNPH and stained
with anti-DNP to detect protein carbonylation, and counterstained with Hoechst in mice from WT·WT and WT·TgSTOX42
crosses (left panels). Right panels indicate fluorescence intensity quantification per surface (area) analyzed; identical surfaces were
assessed in all samples; n=500 surfaces (Labyrinth), and n=100 surfaces (Glycogen cells, Junction zone, and Maternal cells) per
tissue section. Scale bar=50lm.Quantifications are expressed asmean–SD. *p<0.001 for t-test; (WT·TgSTOX42 vs.WT·WT).
DNPH, 2, 4-dinitrophenylhydrazine; SD, standard deviation; STOX1, storkhead box 1; VDAC, voltage-dependent anion channel;
WT, wild-type. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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We then examined the cellular redox metabolism. Ex-
pression levels of GABPA, encoding a factor involved in
mitochondrial biogenesis (7), and Parkinson protein 2
(PARK2) encoding Parkin, a E3 ubiquitin-protein ligase im-
portant for antioxidant defence (76), were increased by
hypoxia in control cells, which was not the case in STOX1-
High cells (Fig. 2B). Furthermore, STOX1 overexpression
was associated with a decrease of PINK1 expression, a mi-
tochondrial serine/threonine protein kinase that prevents
oxidative damage (26). Accordingly, most sirtuins [known to
be induced in response to hypoxia (23) and to inhibit HIF-
mediated hypoxia response (30)], and their downstream ef-
fectors, FOXO1 and FOXO3a, which are activated in the
presence of oxidative stress, were highly expressed in control
cells in hypoxia (19); whereas their levels were reduced in
STOX1High cells at a low O2 concentration (Supplementary
Fig. S2C, D). Moreover, expression levels of antioxidant
enzymes that constitute the main line of defence against ni-
trosative and oxidative stresses (73), such as superoxide
dismutases SOD1 (CU/Zn-SOD) and SOD2 (Mn-SOD),
peroxiredoxins PRDX2 and PRDX5, thioredoxins TRX1 and
TRX2, and glutathione peroxidase GPX1, were lower in
STOX1High compared with control cells at 2% O2 (Fig. 2C).
In addition, at 2% O2 the hypoxia-induced expression of
iNOS was repressed in STOX1High cells (Fig. 2D). STOX1
also reduced the expression of PTPS, SPR, DHFR, and
MTHFR, encoding for enzymes involved in tetra-
hydrobiopterin (BH4) metabolism, which is indispensable for
the transformation of l-arginine to l-citrulline and NO (75).
Altogether, these observations suggest altered NO production
in STOX1High compared with control cells, and particularly
in hypoxia. By contrast, SOD2 and GCH1, which encodes an
early enzyme in BH4 synthesis, were relatively insensitive to
STOX1 but down-regulated by hypoxia (Fig. 2C, D).
The expressions of intracellular oxidases, responsible for
superoxide generation and oxidative stress (5), such as the
NADPH oxidase organizer 1 (NOXO1), the NOX activator 1
(NOXA1), and the dual oxidases (DUOX1 andDUOX2), were
no longer induced by hypoxia when STOX1 was over-
expressed (Fig. 2E). In contrast, the expression of several
NOXs was mildly induced by hypoxia, while it was rather
insensitive to the STOX1 status. To note, we recently re-
ported that pre-eclamptic plasma affects NOX4 expression in
endothelial cells (10). Moreover, STOX1 inhibited hypoxia-
induced expression of the cyclooxygenase-1 (COX-1), and
induced COX-2 expression (Fig. 2E). Taken together, the
FIG. 2. Deregulation by STOX1 overexpression of the expression of genes involved in hypoxia response, antioxi-
dant defense, and nitric oxide metabolism. Quantitative RT-qPCR measurement of key genes involved in response to
hypoxia (A), antioxidant defense/cellular redox metabolism (B), antioxidant enzymes (C), nitric oxide metabolism (D), and
coding for intracellular oxidases (E) in control and STOX1High cells at 20% O2 (white and light grey bars, respectively)
and at 2% (dark gray and black bars, respectively). Statistical analysis was performed by full factorial ANOVA on two
factors (oxygen concentration and STOX1 level). *p < 0.01 for the effects of STOX1 expression relative to control (control
cells at 20% O2),
#p < 0.01 for the effects of oxygen, ip < 0.01 for an interaction effect, that is, for instance a differential
effect of oxygen according to the STOX1 expression level. Results are expressed as mean – SD. Statistical details are given
for each gene in Supplementary Table S4. RT-qPCR, reverse transcription quantitative PCR.
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expression of these genes indicates multiple levels of alter-
ation of NO metabolic pathways on STOX1 overexpression,
including hypoxia-dependent alterations.
In sum, under hypoxia, genes coding for enzymes impli-
cated in free radical production are overall reduced after
STOX1 overexpression; whereas the detoxifying machinery
appears less active, raising questions on the physiological
outcome and balance of these alterations.
STOX1 overexpression affects the mitochondrial mass
We assessed the mitochondrial mass by immunofluores-
cent staining of TOM22 and VDAC on fixed cells and by
labeling living cells with MitoTracker Green, a chemical
dye that labels active mitochondria using the mitochondrial
membrane potential (MMP) (1). These three distinct mea-
surements showed that in control cells the mitochondrial
mass was reduced in hypoxia (Fig. 3A, B and Supplemen-
tary Fig. S3, p > 0.05, p = 4.4 · 10- 12, and 7.5 · 10- 23, for
TOM22, VDAC, and MitoTracker, respectively, comparing
20% O2 and hypoxia). On the contrary, in STOX1High cells,
the mitochondrial mass increased about twofold in hypoxia
(Fig. 3A and Supplementary Fig. S3; p = 5.1 · 10 - 6, > 0.05
and 2.1 · 10- 15, for TOM22, VDAC, and MitoTracker,
respectively comparing 20% O2 and hypoxia).
Consistently, control cells in hypoxia showed a reduced
expression of master regulators of mitochondrial biogene-
sis, PGC1a, PGC1b, and NRF1 [but not GABPA (NRF2A)
and GABPB1, Fig. 3C]. A similar decrease of PGC1b and
NRF1 was also observed in STOX1High cells despite in-
creased mitochondrial mass (see Fig. 3A and Supplemen-
tary Fig. S3), suggesting that in these cells the steady-state
mitochondrial mass is not primarily dependent on organelle
biogenesis.
The mitochondrial mass can be reduced by autophagy, a
nonselective bulk degradation of cytoplasm and organelles,
or by selective autophagy (mitophagy), which eliminates
damaged mitochondria and may result in cell death (54).
Immunofluorescence levels of MAP1LC3B (LC3B), an au-
tophagy factor that comprises the inactive (LC3B-I) and the
autophagosome-associated active (LC3B-II) forms, were re-
duced by hypoxia, and the decrease was larger in STOX1High
cells than in controls (Fig. 3D). Interestingly, the ratio LC3B-
II/LC3B-I, an indicator of autophagy activation (47), was
significantly higher in STOX1High cells than in controls in-
dependently of the oxygen pressure [1.88– 0.06 vs.
1.23– 0.01 at 20% oxygen ( p= 2.7· 10- 4) and 1.85– 0.05
vs. 1.37– 0.03 at 2% oxygen ( p= 7.0· 10- 5); Fig. 3E].
Global mitochondrial fragmentation, which is required
before the LC3B-II-mediated mitochondria engulfment into
autophagosomes in mitophagy, increased under hypoxia but
was not influenced by STOX1 overexpression (Supplemen-
tary Fig. S4A). Strikingly, at 20% O2, dynamin-related pro-
tein 1 (DRP1) (encoding a master regulator of mitochondrial
fission, and inhibitor of autophagosome targeting of mito-
chondria) was *30-fold lower in STOX1High cells than in
control cells. DRP1 reduction may compensate for decreased
mitochondrial content in STOX1High cells. By hypoxia,
DRP1 expression was reduced in control cells (approxima-
tely threefold), whereas it increased in STOX1High cells
(approximately ninefold) (Supplementary Fig. S4B, C).
DRP1 decrease and the apparent absence of mitochondrial
fragmentation suggest the inhibition of mitophagy in
STOX1High cells at 20% O2. These findings concur with
decreased PARK2 expression in STOX1High cells (as shown
above, in Fig. 2B, Expression of genes involved in cellular
redox metabolism), PARK2 translocation to mitochondria
being involved in mitophagy (76). Optic atrophy 1 (OPA1), a
key regulator of mitochondrial fusion, was unaltered (Sup-
plementary Fig. S4D, E).
In conclusion, a decrease of the mitochondrial mass in
STOX1High cells at 20% O2 may depend on activated au-
tophagy rather than mitophagy.
STOX1 overexpression affects mitochondrial function
and energy metabolism
The MMP is the driving force for mitochondrial proteins
import, substrates and ions transport, and, consequently, for
mitochondrial activities (49). A decrease in oxygen pres-
sure led to a 30% reduction of MMP measured by tetra-
methylrhodamine ethyl ester (TMRE) fluorescence in control
cells (59) (Fig. 4A), which was consistent with a decrease in
mitochondrial mass (as shown above, in Supplementary Fig.
S3). Conversely, STOX1High cells display the highest MMP
values in hypoxia. When normalized to the mitochondrial
mass (TOM22), the MMP of STOX1High cells was always
higher than control cells (hypoxia p= 1.3 · 10- 9, 20% O2
p = 1 · 10- 4, Fig. 4B), indicating more mitochondrial activity
in STOX1High than in control cells.
Global cellular oxidative phosphorylation capacity was
assessed at 20% O2. STOX1High cells maintained normal
respiration rate and cellular adenosine triphosphate (ATP)
concentration (Fig. 4C, D). Consequently, ATP levels nor-
malized to the mitochondrial mass (TOM22) are almost
threefold higher in STOX1High than in control cells (Fig.
4E). Altogether, at both O2 concentrations, mitochondria
appear more active in STOX1High than in control cells.
Compared with the other conditions, STOX1High cells at
2% O2 showed a 50% decrease of the mtDNA content (Fig.
4F), but increased levels of TFAM, a factor involved in
mtDNA transcription, replication, and maintenance (Sup-
plementary Fig. S5A–C), with an approximately fourfold
higher ratio of TFAM/mtDNA. POLG, the DNA polymerase
that replicates mtDNA, was affected by hypoxia (Supple-
mentary Fig. S5D, E). Thus, STOX1High cells displayed
higher levels of POLG relative to the mitochondrial mass
than control cells (POLG/TOM22, 1.7-fold in hypoxia and
3.2-fold at 20% O2) (Supplementary Fig. S5F).
We also evaluated mtDNA maintenance using a novel
validated imaging fluorescence in situ hybridization ap-
proach, mitochondrial transcription, and replication im-
aging protocol (mTRIP) to assess mtDNA initiation of
replication (13, 14). The levels of mitochondrial replica-
tion marker (mREP) (a probe that signals the D-loop
opening for mtDNA replication) per cell were similar in
all situations (Supplementary Fig. S5G, H), as were the
levels of a mixture of probes that target several mito-
chondrial RNAs (mTRANS; Supplementary Fig. S6A, B).
mtDNA-encoded genes were expressed at normal levels in
STOX1High cells in hypoxia (Supplementary Fig. S6C)
despite lower mtDNA content. Taking into account the
reduced TOM22 levels, STOX1High cells at 20% O2
displayed a two- to three-fold higher mREP and mTRANS
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FIG. 3. Mitochondrial mass, mitochondrial biogenesis markers, and mitophagy/autophagy in STOX1 over-
expressing cells. (A) Three-dimensional-reconstructed cells immunostained with anti-TOM22 (green) to detect the mito-
chondrial mass; nuclei are stained with Hoechst (blue). Right panel, fluorescence intensity quantification of TOM22 per cell.
(B) Western blot of TOM22, internal reference GAPDH, and loading control SYPRO Ruby. The ratio of TOM22 signal
normalized first to GAPDH and then to control cells at 2% O2 is indicated; n = 3 experiments, – SD. (C) Quantitative RT-
qPCR of mitochondrial biogenesis factors PGC1a, PGC1b, NRF1, GABPA, and GABPB1. Statistical analysis was per-
formed as described for Figure 2. i = interaction effect between the factor ‘‘STOX1 expression’’ and the factor ‘‘Hypoxia’’
estimated by Analysis of Variance as described in Material and Methods, section ‘‘Statistical Analysis.’’ (D) Three-
dimensional-reconstructed cells immunostained with anti-MAP1LC3B (microtubule-associated proteins 1A/1B light chain
3B; or LC3B, green) and counterstained with Hoechst (blue). Right panel, fluorescence intensity quantification of
MAP1LC3B per cell. (E) Western blot of inactive (I) and active (II) forms of LC3B-I, internal reference GAPDH, and
loading control SYPRO Ruby. The ratio of either LC3B-I or LC3B-II signal normalized first to GAPDH and then to control
cells is normalized to 1 at 20% O2. The ratio of LC3B-II/I is calculated after normalization of the two forms to GAPDH;
n= 3 experiments,–SD. Scale bar= 10lm. Immunofluorescence,n= 30 cells from three independent experiments, per condition.
t-Tests were used in these experiments; *p< 0.001 STOX1High versus control cells; #p< 0.001 20% versus 2% O2. TOM22,
LC3B, VDAC (Supplementary Fig. S3A), and GAPDHwere revealed from the same blot (molecular weight, 22, 14–16, 30, and
37kDa, respectively). Quantifications are expressed as mean–SD. NRF1, nuclear respiratory factor 1. To see this illustration in
color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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signal per mitochondrial mass than control cells (Sup-
plementary Figs. S5H and S6B).
The expression of key genes involved in mtDNA mainte-
nance and mitochondrial transcription (Supplementary Fig.
S6D, E) was not correlated with the levels of mtDNA tran-
scription. Rather, the expression of these factors increased in
control cells in hypoxia, but not in STOX1High cells, indi-
cating a failure of STOX1High cells to adapt to hypoxia by
varying the expression of mtDNA processing factors.
In summary, under hypoxia, STOX1High cells maintain
mitochondrial mass despite an apparent lack of adaptation.
These cells display reduced mtDNA content and increased
MMP. At 20% O2, STOX1High cells maintain ATP pro-
duction, O2 consumption, and mtDNA content despite re-
duced mitochondrial mass and MMP.
In support of the notion that hypoxia is associated with
increased oxidative stress in our system, we observed alter-
ations of key mitochondrial factors (immunofluorescence of
TOM22, TFAM, POLG, and DRP1) comparable to those
observed in hypoxia when STOX1High cells at 20% Oxygen
were treated with H2O2 (Supplementary Table S5).
STOX1 overexpression induces
nitroso-redox imbalance
We then analyzed oxidative stress in STOX1High cells in
hypoxia and at 20% O2 using dihydrorhodamine 123
(DHR123) and 2¢,7¢-dichlorofluorescein diacetate DCFH-
DA, two fluorescent probes with preferential sensitivity
for RNS and ROS, respectively (22). In control cells, the
FIG. 4. Mitochondrial metabolism in STOX1 overexpressing cells. (A) Three-dimensional-reconstructed cells stained
with TMRE (red) to detect the mitochondrial membrane potential; nuclei (blue) are stained with Hoechst. Right panel,
fluorescence intensity quantification of TMRE per cell. n= 30 cells from three independent experiments, per condition; scale
bar = 10lm. (B) Ratio of TMRE/TOM22 (for each factor, average value of three independent experiments; values of
TOM22 are from Fig. 3A normalized to control cells at 20% O2). (C) Oxygen consumption, pmol O2 per second and per
million cells. n = 3 experiments per condition. (D) ATP steady-state level, mmol per mg protein. n = 3 experiments per
condition. (E) Ratio of mitoATP (deoxyglucose)/TOM22 (for each factor, average value of three independent experiments;
values of TOM22 are from Fig. 3A), normalized to control cells at 2% O2. (F)MtDNA content of cells analyzed by qPCR in
the 12S region. n = 3 experiments. Quantifications are expressed as mean – SD. * Significant effect of STOX1, # significant
effect of O2. ATP, adenosine triphosphate; TMRE, tetramethylrhodamine ethyl ester. To see this illustration in color, the
reader is referred to the web version of this article at www.liebertpub.com/ars
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FIG. 5. Imbalanced nitroso-redox equilibrium in STOX1 overexpressing cells. (A) Three-dimensional-reconstructed
cells stained with DHR123 (green) for the determination of a relative enrichment in intracellular peroxynitrites with or without
treatment of the RNS scavenger uric acid at 300lM. Right panel, fluorescence intensity quantification of rhodamine 123 per
cell (control cells in white and STOX1High cells in black). Each experiment was performed in triplicate.‘‘*’’ Marks
significant Student’s t-test for the effect of each scavenger versus its absence. ‘‘#’’ Marks significant oxygen effects and ‘‘*’’
marks significant effect of STOX1 overexpression, in (A, B). (B) Three-dimensional-reconstructed cells stained with DCFH-
DA (green) for the determination of relative enrichment in intracellular ROS with or without treatment with the ROS
scavenger NAC. Right panel, fluorescence intensity quantification of DCF per cell (control cells in white and STOX1High
cells in black). (C) Three-dimensional-reconstructed cells stained with anti-3-nitrotyrosine (red) to detect protein nitration.
Right panel, fluorescence intensity quantification of nitrated proteins per cell. (D) Three-dimensional-reconstructed cells
stained with DNP and anti-DNP (red). Right panel, fluorescence intensity quantification of carbonylated proteins per cell.
Nuclei are stained with Hoechst (blue). Scale bar= 10lm. n= 30 cells from three independent experiments per condition.
Quantifications are expressed as mean–SD. For the Student’s t-test: * stands for significant effect of STOX1 overexpression, #
for significant oxygen effect, and * for significant effect of each scavenger. DCFH-DA, 2¢,7¢-dichlorodihydrofluorescin
diacetate; DHR123, dihydrorhodamine 123; NAC, N-acetyl cysteine; RNS, reactive nitrogen species; ROS, reactive oxygen
species. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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DHR123 signal increased at higher oxygen pressure; whereas
the reverse was observed with DCFH-DA (Fig. 5A, B). The
profile was strictly opposite in STOX1High cells. The switch
from ROS to RNS signal (or vice versa) is compatible with
ROS and NO competitively targeting Cys residues (42). The
specificity of ROS and RNS labeling by DCFH-DA and
DHR123, respectively, was analyzed at 20% O2 and hypoxia
in the presence of the RNS scavenger uric acid and the ROS
inhibitor N-acetyl cysteine (NAC). We observed a systematic
decrease of ROS and RNS labeling using the specific scav-
enger although, curiously, the decrease was not significant for
NAC in hypoxia. It is possible that this cell line harbors
resistance to NAC in hypoxia, although to our knowledge this
has not been assessed. Altogether, these analyses confirm
opposite ROS and RNS profiles in STOX1High versus con-
trol cells according to the oxygen pressure.
We then evaluated the steady-state levels of protein oxi-
dative adducts, either nitration (due to RNS) or carbonylation
(due to ROS) (65, 66) (Fig. 5C, D). STOX1High cells in
hypoxia displayed a higher level of protein nitration and lower
level of carbonylation than control cells, whereas the reverse
pattern was observed at 20%O2. These results were confirmed
by Western blot (Supplementary Fig. S7A, B). The nitroso-
redox balance, thus, appears dependent on oxygen pressure,
and it is strongly modified by STOX1 overexpression.
Discussion
In the present study, we uncover a novel function of the
pre-eclampsia-associated transcription factor STOX1 as a
master regulator of the oxygen-dependent nitroso-redox
balance. Although after the discovery of this gene the role of
STOX1 in pre-eclampsia has been questioned (31), the
original study (71) and a more recent one (6) concur to ob-
serve an association between STOX1 and the familial forms
of pre-eclampsia. Briefly, the original study (71) identified
the more abundant STOX1 Y153H polymorphism in a sub-
population of Dutch where pre-eclampsia and gestational
hypertension had a strong familial component. Moreover, the
study of Berends et al. (6), focusing on a ‘‘familial’’ sub-
population of samples, observed an association between
STOX1 and the forms of pre-eclampsia with a strong familial
component. In contrast, this polymorphism was not found to
be associated with the disease in other populations where the
pre-eclampsia was sporadic (31, 37). Moreover, the im-
printed status of STOX1 was questioned at the global pla-
cental level (31); whereas mono-allelic methylation and
expression of this gene were detected in specific cell types of
the placenta (extravillous column cytotrophoblasts) (70), and
an independent study showed interindividual variation in the
imprinting status of STOX1 (15). In agreement with the
implication of STOX1 in pre-eclampsia, overexpression of
STOX1 was observed in early placental biopsies in gesta-
tions, eventually progressing to pre-eclampsia [GSE12767 in
Founds et al. (20)]. Furthermore, we induced pre-eclampsia-
like symptoms in two independent mouse strains over-
expressing STOX1 (TgSTOX13 and TgSTOX42) (18). In the
present study, we focused on the strain harboring the most
severe phenotype, TgSTOX42.
We show here that hypoxia affects trophoblasts in culture,
and that STOX1 overexpression exacerbates this effect,
thereby suggesting a double-hit model, where in excess of
STOX1, trophoblasts do not adapt to hypoxic conditions. We
found a striking down-regulation of miR-210 in JEG-3 hyp-
oxic cells overexpressing STOX1. MiR-210 is increased in
pre-eclampsia; our data, thus, suggest that STOX1 over-
expression mitigates an adaptive process mediated by miR-
210. STOX1 overexpression triggers a reduced expression of
genes involved in DDR and cholesterol metabolism, two
pathways that are altered in pre-eclampsia. However, the
most striking effect is the imbalance of ROS and RNS in-
duced by STOX1 overexpression in cells and placentas. The
capture of NO by STOX1 overexpressing placentas is pro-
posed here as a mechanism to explain increased blood pres-
sure in pre-eclampsia, consistently with existing literature
(34, 63). In human gestation, the blood flow in the placenta
near term is around 600ml/min, which is theoretically able to
drive a rapid and strong decrease of NO in the whole maternal
body during pre-eclampsia. Modulating the ROS/RNS bal-
ance could be considered an innovative strategy to treat pre-
eclampsia, possibly by BH4 treatment or uric acid precursors
(60). In this case, our mouse model is a potentially excellent
platform for testing therapeutic approaches in the future.
An abundant literature exists on oxidant molecules asso-
ciated with pre-eclampsia (48). RNS and ROS stresses are
generally treated as a whole (17). It is widely assumed that
the sites of peroxynitrite generation are spatially associated
with the sources of superoxide production (such as mito-
chondria) in the context of hypoxia and inflammation (51).
Peroxynitrite ions nitrate tyrosine residues and have been
shown to be elevated in pre-eclampsia (45). Peroxynitrite is
associated with biological toxic effects that are also found
in pre-eclampsia (62) such as antioxidant depletion (68),
deregulation of COXs (3), NOS uncoupling (58), lipid per-
oxidation (24), insulin resistance (52), imbalance of pro-
and anti-inflammatory mediators (12), neuro-inflammatory
disease/stroke (52), DNA damage (21), mitochondrial dys-
function (50), and renal injury associated with proteinuria
and high plasma uric acid level (52). Nitrotyrosine strongly
marks the vasculature of pre-eclamptic placentas (8). Re-
cently, uric acid has been reported to mark hypertension and
endothelial damage in pre-eclampsia (41). Thus, uric acid
could be considered a physiological protective response
against peroxynitrite accumulation, as it is a natural strong
peroxynitrite scavenger that inhibits inflammation (27).
Peroxynitrite also affects the BH4 pathway and produces a
vicious circle of peroxynitrite generation.
Finally, nitrosative and oxidative stresses target mitochon-
dria (53), which we analyzed by multiple approaches, espe-
cially integrative methods of quantitative immunofluorescence
(13, 14). At low oxygen pressure, overexpression of STOX1
did not change the mitochondrial mass in the cells, which
increased in transgenic placentas, suggesting that homeostatic
processes at work in the organs are absent in the cells. This
discrepancy is consistent with recent literature (43). Similarly,
VDAC was found to be increased by proteomic analysis in the
pre-eclamptic placenta (36), which is consistent with our data
(Fig. 1C); whereas it was not altered in cells at low oxygen
pressure and even reduced at high oxygen pressure.
Views of the immunohistochemical alterations that char-
acterize the control versus STOX1High cells are presented as
a Principal Component Analysis in Figure 6A. Control cells
at 2% O2 present intermediate features between STOX1
High cells at 2% and 20% O2, suggesting that STOX1
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FIG. 6. Meta-analysis of STOX1 overexpressing cells. (A) Principal Component Analysis with the quantitative immu-
nofluorescence data from peroxynitrite, ROS, protein nitration, protein carbonylation, TOM22, TFAM, mtDNA content, POLG,
mREP, mTRANS, OPA1, DRP1, LC3B, and TMRE. The two first axes represent more than 49% (29%+ 20%) of the overall
variation. It clearly appears that STOX1High cells are not able to respond adequately to hypoxia and are close to control cells
which are already in hypoxic conditions. (B) Proposed model in normal physiology and pre-eclampsia/STOX1 overexpressing
cells representing the cellular and molecular bases of the effects of STOX1 (see also text). First, for many genes, the effects of
STOX1 depend on the oxygen pressure, as shown by significant interaction effects. STOX1 overexpression down-regulates the
expression of key hypoxia regulators, such as HIF1a, HIF1b and drastically miR-210, possibly inducing a defective response to
hypoxia both in vitro and in vivo. Key transcription factors, including FOXOs and Sirtuins, that are involved in lipid metab-
olism, nitric oxide metabolism, oxidases, antioxidant defense, and mitochondrial function are dramatically altered. The com-
bined deregulation of these factors and STOX1 overexpression affect the nitric oxide metabolism [NOS uncoupling, NO
bioavailability, and ONOO- generation: alteration of BH4 destabilizes NOS, which uncoupled, will alternatively produce O2-
and NO, and form highly reactive peroxynitrite ions (ONOO- )] (2, 75), oxidant generation (O2- ), antioxidant defense,
mitochondrial function and metabolism, DDR, and cholesterol metabolism. This analysis suggests a mechanism by which
STOX1 overexpression activates a powerful NO pump that may deprive the maternal endothelium of this molecule, thereby
contributing to the pre-eclamptic phenotype. DDR, DNA damage response. BH4, tetrahydrobiopterin; DRP1, dynamin-related
protein 1; mREP, mitochondrial replication marker; mTRANS, a mixture of probes that target several mitochondrial RNAs;
NOS, nitric oxide synthase; OPA1, optic atrophy 1; POLG, polymerase (DNA directed), gamma; TFAM, transcription factor A,
mitochondrial. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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overexpression interferes with oxygen sensors and somehow
putting the cells in an artificial ‘‘hypoxic’’ state.
In agreement with these findings, and underscoring the
misregulation of oxidative stress management when STOX1
is overexpressed, we observed comparable effects on mito-
chondrial factors in STOX1High cells grown either under
hypoxia or at 20% O2 in the presence of the highly oxidizing
factor H2O2. Moreover, in the presence of H2O2, STOX1-
High cells displayed a global increase of mitochondrial pa-
rameters; whereas it was the opposite for control cells.
In hypoxia, STOX1High cells contain a damaging and
toxic cocktail with accumulation of peroxynitrite and rela-
tively high level of ROS. The mtDNA content is reduced but
appears highly protected by TFAM, and the mitochondrial
mass is not affected, probably resulting from the balance
between increased mitochondrial biogenesis (marker PGC1a)
and increased level of the autophagy (LC3B-II/I). At high
oxygen pressure, STOX1High cells have nearly the same
damaging cocktail except that peroxynitrite levels decrease
and the ROS levels increase. The mitochondrial mass is also
dramatically reduced due to a strong increase of LC3B, which
activates autophagy, and to DRP1 deficiency. However, to
maintain stable total ATP level, the remaining mitochondria
appear hyper-activated (increased membrane (Fig. 6B) po-
tential, increased mtDNA replication, and transcription levels
per mitochondrial mass unit). This led us to a model (Fig. 6B)
presenting cellular and molecular bases of STOX1 effects
in the context of mitochondrial function and pre-eclampsia.
Materials and Methods
Mouse placentas and microarray experiment
Four- to eight-month-old male and female mice with the
FVB/N genetic background were used throughout this study,
bred in the animal facility of Institut National de Recherche
Agronomique (INRA, Jouy en Josas, France) in a controlled
environment (light/dark cycle, temperature, free access to
food and water) in accordance with local ethical regulations.
RNA was extracted from placentas in TriZol following
classical protocols at 16.5 dpc from three different mice
of each group as previously described (18). Quality control of
the RNA, preparation of the probes, and hybridization on
Nimblegen Mouse Expression Arrays MM8 were performed
at the genom’IC platform (Cochin Institute, Paris, France)
according to standard protocols. Data from this experiment,
fulfilling the Minimum Information About a Microarray
Experiment (MIAME) criteria, were deposited in the func-
tional genomics ArrayExpress database of the EMBL-EBI
web server (accession number E-MTAB-1970). Data were
analyzed using GSEA (www.broadinstitute.org/gsea/in-
dex.jsp). This program compares the experimental dataset
with a series of pathways (67), analyzes the distribution of the
genes of the dataset present in the given pathways, and tests
by simulation the randomness of their distribution. Generally,
the program is set to a FDR of 0.25.
Cell culture and hypoxia
Modified JEG-3 cells (control cells, stably transfected with
an empty pCMX vector, and STOX1High cells, stably
transfected with a pCMX-STOX1A vector) (56) were grown
in Dulbecco’s modified Eagle’s medium Glutamax (Life
Technologies, Carlsbad, CA) with 10% of heat-inactivated
fetal calf serum (Life Technologies), 1% penicillin/strepto-
mycin, and 1% of geneticin at 37C in the presence of 5%
CO2. Cells seeded overnight in wells containing glass dishes,
on sterile glass slides, were placed in a Lwoff chamber at
37C and exposed to an oxygen-depleted atmosphere for 24 h
(2% O2, 5% CO2) or maintained at 37C in a humidified
normal atmosphere (20% O2, 5% CO2) for 24 h. The exper-
iments were performed independently thrice, each in tripli-
cate. When indicated, cells were grown in 20% O2 in the
presence of 150 lm H2O2 for 24 h.
Reverse transcription quantitative polymerase
chain reaction
Total RNA was isolated and reverse transcribed accord-
ing to standard protocols. RT-qPCR was performed using
LightCycler 480 SYBRGreen I Master containing FastStart
Taq DNA Polymerase, and the rate of dye incorporation was
monitored using a LightCycler 480 Instrument II and the
LightCycler software (Roche, Basel, Switzerland) in the
exponential phase of the PCR reaction. Each RT-qPCR was
carried out in technical duplicates from a pool of three bio-
logical replicates, using TBP transcript levels for normali-
zation. RT-qPCR CT values were analyzed using the 2-DDCT
method to calculate the fold expression (40). Primers used for
amplifications are listed in Supplementary Table S3 with the
corresponding references.
Quantification of miRNA-210 followed the protocol of
Sdassi et al. (61). A polyA tail was added to RNA by Poly-A
polymerase treatment (Life Technologies). After phenol-
chloroform treatment in the presence of glycogen as a carrier,
and isopropanol precipitation, reverse transcription was car-
ried out from a universal primer 5¢-CGAATTCTAGA
GCTCGAGGCAGGCGACATGGCTGGCTAGTTAAGCT
TGGTACCGAGCTCGGATCCACTAGTCCTTTTTTTTT
TTTTTTTTTTTTTTTTTVN-3¢. Quantitative PCR was
performed using the Universal and miR-210-specific prim-
ers (5¢-CGAATTCTAGAGCTCGAGGCAGG-3¢ and 5¢-
CTGTGCGTGTGACAGCGGCTGA-3¢, which is identical
for humans and mice), using 5S RNA as a reporter gene.
mtDNA content analysis by qPCR
DNA was extracted under standard procedures. Quantita-
tive PCR was performed in duplicates from three biological
replicates using LightCycler 480 SYBR Green I Master
containing FastStart Taq DNA Polymerase, LightCycler 480
Instrument II, and LightCycler software (Roche). The region
tested on mtDNA was included in the 12S gene. 18S rRNA
gene was used as a reference. The level of mtDNA was cal-
culated using the DCT of average CT of mtDNA and nuclear
DNA (DCT =CT nDNA–CT mtDNA) as 2DCT. Primers
used for amplifications are listed in Supplementary Table S3.
Immunofluorescence, reagents, and antibodies
Cells seeded on slides were fixed with 2% paraformalde-
hyde (PFA) and permeabilized with 0.5% Triton X-100.
Slides were incubated in blocking buffer (5% bovine serum
albumin [BSA] in phosphate-buffered saline [PBS]) over-
night at 4C, then with the primary antibody for 1 h at room
temperature (RT), and, finally, with the secondary antibody
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and 10 lg/ml of Hoechst 33342 for 1 h at RT. Atto488-con-
jugated anti-TOM22, anti-MAP1LC3B, and Hoechst 33342
were from Sigma-Aldrich (St Louis, MI); TFAM, Polc,
VDAC 1/2/3 (sc-98708), OPA1, DRP1, and GAPDH anti-
bodies were from SantaCruz Biotechnology (Dallas, TX);
and MitoTrackerGreen FM, Alexa Fluor 555, and Alexa
Fluor 488-conjugated secondary antibodies were from Life
Technologies.
MMP was measured with 200 nM TMRE (Sigma-Aldrich)
for 1 h at 37C, 5% CO2, and 2% or 20% O2.
Immunohistochemistry of placentas was performed onWT
or transgenic placentas (expressing the human STOX1 under
the control of the cytomegalovirus promoter) (18). Mice were
sacrificed near the end of gestation (E16.5). Four WT pla-
centas from two (WT ·WT) crosses and seven placentas
from four (WT ·TgSTOX42) crosses were analyzed for
TOM22 immunofluorescence, and for protein nitration and
carbonylation. Placental regions, ascertained by periodic acid
Schiff staining of adjacent sections, were analyzed by im-
munostaining on slides from paraffin-embedded placentas
(5 lm). Placental sections were dewaxed in 2% DishWasher
Soap, 1 · PBS for 5min at 70C, and then prepared according
to the specific immunofluorescence procedure.
Detection of peroxynitrite, ROS, and protein oxidation
and carbonylation
Peroxynitrite was detected after treatment of the cells at
10 lM of the cell-permeant nonfluorescent DHR123 (Sigma-
Aldrich) oxidized in green fluorescent rhodamine in the
presence of peroxynitrite. ROS (mainly O2 - and H2O2) were
detected after treatment with 10 lM of the cell-permeable
nonfluorescent 2¢,7¢-dichlorodihydrofluorescin diacetate
(DCFH-DA; Sigma), oxidized to form green fluorescent
2¢,7¢-dichlorofluorescein (DCF), in the presence of ROS (16).
Protein nitration was detected with the 3-nitrotyrosine-
specific antibody (Ref: A21285; Life Technologies/Invitrogen).
Protein carbonylation was detected by dinitrophenyl treat-
ment, followed by labeling with the DNP-specific anti-
body using standard procedures (44). Slides were treated
with 0.01% (100lg/ml) 2,4-dinitrophenylhydrazine (DNPH)
(Sigma-Aldrich) in 2N HCl for 1 h at RT in the dark, washed
seven times with PBS, blocked with 5% BSA in PBS over-
night at 4C, then treated with the primary anti-DNP antibody
(Merck Millipore, Darmstadt, Germany) for 1 h at RT, and,
finally, with the secondary antibody and 10lg/ml of Hoechst
33342 for 1 h at RT. When mentioned, the cells were treated
for 24 h with uric acid (300lM final), or with NAC (2mM
final), both of which had been purchased from Sigma-Aldrich.
Mitochondrial transcription and replication
imaging protocol
DNA probes (mREP andmTRANS) for the fluorescence in
situ hybridization protocol called mTRIP were labeled by
nick translation of PCR products, incorporating Atto550-
dUTP (Atto550 NT Labeling kit; Jena Bioscience, Jena,
Germany), as described (14). Forty nanograms of labeled
probes were mixed with 400 ng of sonicated salmon sperm
DNA (Sigma-Aldrich) in the hybridization buffer [50%
formamide, 10% dextran sulfate, in 2 · saline-sodium citrate
(SSC) buffer pH 7.0], denatured at 80C for 10min, and then
maintained at 37C for 30min. Cells seeded on slides were
fixed with 2% PFA, permeabilized with 0.5% Triton X-100,
incubated in 50% formamide/2 · SSC pH 7.0 for 30min at
RT, and denaturated in 70% formamide/2 · SSC for 4min at
75C. Hybridization was performed with 40 ng of probe for
16 h at 37C. Slides were washed in SSC, and nuclei were
counterstained with 10lg/ml of Hoechst 33342.
Three-dimensional confocal acquisition,
reconstruction, and quantification
Confocal acquisition was performed using an inverted la-
ser-scanning confocal microscope Zeiss Axiovert 200M with
a spinning-disk Perkin-Elmer Ultraview RS Nipkow Disk, an
Apochromat 63· /1.4 oil objective for fixed cells or an 25· oil
objective formice placenta section, and a Hamamatsu ORCA-
II-ER camera (Imagopole, PFID; Institut Pasteur, Paris,
France). Optical slices were taken every 200-nm interval
along the z-axis covering the whole depth of the cell, at a
resolution of 1.024/1.024 pixels. Three-dimensinal recon-
struction was achieved using the IMARIS software (Bitplane,
South Windsor, CT). Post-acquisition analysis and fluores-
cence quantification were done using a single-imaging frame
collection and ImageJ 1.38· software. For each sample, 30
cells were analyzed from three independent experiments.
Oxygen consumption and total ATP steady-state level
High-resolution respirometry was performed on 106 intact
cells per ml of culture medium at 20% O2 (38). Subsequent
sequential additions were as follows: 0.5 lg/ml oligomycin to
measure leaks, successive 1 lM doses of the protonophore
carbonyl cyanide m-chlorophenyl hydrazone (cccp) up to
the maximal respiration rate, and, finally, 1mM KCN to eval-
uate nonrespiratory oxygen consumption. Reserve respiration
was defined as the difference between maximal and basal
respiration rate.
ATP steady-state level was measured by the ATP chemilu-
minescent assay (Roche, Mannheim, Germany) and normal-
ized to the amount of cellular protein. Cells were incubated in
the culture medium (basal) for 15 h with 1lM oligomycin to
inhibit mitochondrial ATP synthesis or without glucose but
with 10mM deoxyglucose to inhibit glycolysis.
Protein extraction and immunoblot
Cells were lysed in 50mM Tris-HCl pH 7.5, 150mM
NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS),
1mM EDTA, and protease inhibitor cocktail. Thirty micro-
grams of protein, estimated by Bradford reactions (Sigma-
Aldrich), were loaded for SDS-PAGE. After blotting,
Hybond ECL nitrocellulose filters were probed with primary
antibodies, then with IRDye secondary antibodies. Detection
was performed using Odyssey Infrared Imaging system
scanner and Odyssey application software v3.0 (LI-COR
Biosciences, Lincoln, NE). OPA1, DRP1, and TFAM (Sup-
plementary Fig. S5) were revealed from the same blot as well
as GAPDH and the loading test by SYPRO Ruby (molecular
weight, 92, 80, 28, and 37 kDa, respectively).
Protein bands were quantified, normalized to GAPDH, and
then normalized to control cells grown at 20% O2. Since
GAPDHmay vary under hypoxia, a second normalizationwas
done with SYPRO Ruby Protein Blot Stain according to the
manufacturer’s protocol (Life Technologies). Experiments
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were done in triplicate, and a representative Western blot was
presented. For the carbonylated protein level (DNPH deriva-
tization), the protein extracts were treated according to the
protocol of OxyBlot Protein Oxidation Detection Kit (Merck
Millipore).
Statistical analysis
Statistical tests were performed using StatistiXL, a pack-
age running as an Add-in toWindows versions ofMicrosoft’s
Excel spreadsheet program. The RT-qPCR experiments were
analyzed by Full Factorial ANOVA. The detailed statistical
results are given in Supplementary Table S4 for 81 genes
analyzed. The effect of STOX1 is reported as ‘‘STOX1 sta-
tus,’’ the effect of Oxygen (2% or 20%) as ‘‘Oxygen status,’’
and the possible interaction between the two factors as
‘‘Oxygen status*Stox1 status.’’ For immunohistochemistry
and Western blots, Student’s t-tests were performed. In the
figures, significant effects of oxygen are represented with the
symbol ‘‘#,’’ whereas significant effects of STOX1 over-
expression are indicated with the symbol ‘‘*.’’ Significant
interaction effects are indicated by ‘‘i.’’
Multidimensional analyses (Principal Component Analy-
sis) were performed on quantifications of fluorescent data, for
building Figure 6A.
In this study, p < 0.001 was considered significant for im-
munohistochemistry and Western blot experiments; p < 0.01
for RT-qPCR and qPCR (for mitochondrial DNA content).
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Abbreviations Used
ATP¼ adenosine triphosphate
BH4¼ tetrahydrobiopterin
BSA¼ bovine serum albumin
COX¼ cyclooxygenase
DCFH-DA¼ 2¢,7¢-dichlorodihydrofluorescin diacetate
DDR¼DNA damage response
DHFR¼ dihydrofolate reductase
DHR123¼ dihydrorhodamine 123
DNPH¼ 2,4-dinitrophenylhydrazine
DRP1¼ dynamin related protein 1
DUOX¼ dual oxidase
FDR¼ false discovery rate
FOXO1¼ forkhead box protein O1
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Abbreviations Used (Cont.)
FOXO3a¼ forkhead box protein O3a
GABPA¼GA-binding protein transcription factor,
alpha subunit 60kDa
GABPB1¼GA-binding protein transcription factor,
beta subunit 1
GCH1¼GTP cyclohydrolase 1
GSEA¼Gene Set Enrichment Analysis
HIF¼ hypoxia-inducible factor
iNOS¼ nitric oxide synthase 2, inducible
MAP1LC3B¼microtubule-associated protein 1 light chain
3 beta
MMP¼mitochondrial membrane potential
mREP¼mitochondrial replication marker
(labeling D-loop opening)
MTHFR¼methylenetetrahydrofolate reductase
(NAD(P)H)
mTRANS¼ a mixture of probes that target several
mitochondrial RNAs
mTRIP¼mitochondrial transcription and replication
imaging protocol
NAC¼N-acetyl cysteine
NO¼ nitric oxide
NOS¼ nitric oxide synthase
NOX¼NADPH oxidase
NOXA1¼NOX activator 1
NOXO1¼NADPH oxidase organizer 1
NRF1¼ nuclear respiratory factor 1
NRF2A¼GABPA, GA-binding protein transcription
factor, alpha subunit 60kDa
OPA1¼ optic atrophy 1 (autosomal dominant)
PAGE¼ polyacrylamide gel electrophoresis
PARK2¼Parkinson protein 2, E3 ubiquitin protein
ligase (Parkin)
PBS¼ phosphate-buffered saline
PFA¼ paraformaldehyde
PGC1a¼ peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
PGC1b¼ peroxisome proliferator-activated receptor
gamma, coactivator 1 beta
PINK1¼ PTEN-induced putative kinase 1
POLG¼ polymerase (DNA directed), gamma
PRDX2¼ peroxiredoxin 2
PRDX5¼ peroxiredoxin 5
PTPS¼ 6-pyruvoyltetrahydropterin synthase
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
RT¼ room temperature
RT-PCR¼ reverse transcription quantitative
polymerase chain reaction
SD¼ standard deviation
SDS¼ sodium dodecyl sulfate
sENG¼ soluble endoglin
sFLT-1¼ soluble fms-related tyrosine kinase 1
SOD2¼ superoxide dismutase 2, mitochondrial
SPR¼ sepiapterin reductase
(7,8-dihydrobiopterin:NADP+
oxidoreductase)
SREBP1A¼ sterol regulatory element binding
transcription factor 1, isoform A
SREBP1C¼ sterol regulatory element binding
transcription factor 1, isoform C
SSD¼ saline-sodium citrate
STOX1¼ storkhead box 1
TFAM¼ transcription factor A, mitochondrial
TMRE¼ tetramethylrhodamine ethyl ester
TOM22¼ translocase of outer mitochondrial
membrane 22 homolog (yeast)
TRX1¼ thioredoxin 1
TRX2¼ thioredoxin 2
VDAC¼ voltage-dependent anion channel
WT¼wild-type
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